Wildfire Related Air Pollution Exposure and Cognitive Function Pilot Study
WRAP
A Controlled Human Environmental Study Evaluating the Impacts of Cognitive Functions During the Exposure of Simulated Wildfire-Related Air Pollution (WRAP).
1 other identifier
interventional
12
1 country
1
Brief Summary
This study will examine how breathing wildfire-related air pollution (WRAP) for one hour affects healthy adults. The main question the study will answer if the effect of WRAP exposure on p-tau, a blood marker of cognitive decline. The changes in p-tau concentrations after exposure to WRAP will be compared to the changes in p-tau after exposure to clean air. Participants will:
- Have 2 study visits - one visit with exposure to clean air and one visit with exposure to simulated wildfire smoke
- Have blood drawn before and after each exposure
- Complete cognitive tests and memory tasks before and after each exposure
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2025
CompletedFirst Posted
Study publicly available on registry
September 3, 2025
CompletedStudy Start
First participant enrolled
September 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2025
CompletedDecember 2, 2025
November 1, 2025
2 months
August 25, 2025
November 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in plasma P-tau 217 concentration from pre-exposure to post-exposure
Using blood samples collected pre- and post-exposure, the primary outcome will be assessed by measurement of plasma phosphorylated tau at threonine 217 (p-tau217) using an ultrasensitive immunoassay
Immediately before, immediately after each exposure
Study Arms (2)
Exposure to simulated wildfire smoke, then exposure to clean air
EXPERIMENTALAt the first study visit the subject undergoes a 1-hour chamber exposure to simulated wildfire smoke (300 ug/m3 Particulate Matter). After a 1-week washout period, the subject undergoes a 1-hour chamber exposure to clean air (0 ug/m3 PM).
Exposure to clean air, then exposure to simulated wildfire smoke
EXPERIMENTALAt the first study visit the subject undergoes a 1-hour chamber exposure to clean air (0 ug/m3 PM). After a 1-week washout period, the subject undergoes a 1-hour chamber exposure to simulated wildfire smoke (300 ug/m3 PM).
Interventions
1 hour exposure to simulated wildfire smoke (300 ug/m3 PM)
1 hour exposure to clean (HEPA-filtered) air (0 ug/m3 PM)
Eligibility Criteria
You may qualify if:
- Healthy
- Non smoker
- Weight at least 110 pounds
- Between ages 18 and 40 years old
You may not qualify if:
- Claustrophobia or not comfortable in enclosed spaces.
- Colorblindness.
- Inability to hear verbal instructions.
- Cardiovascular disease which, in the opinion of the investigator, would elevate the participant's risk of adverse effects to WRAP exposure. This includes a history of stroke.
- Diabetes requiring the use of insulin.
- Pregnancy (A pregnancy test will be provided to you).
- Current asthma (an asthma attack within the past five years).
- History of childhood asthma.
- Medications which may affect cognition such as beta-blockers and CNS depressants.
- Respiratory symptoms in the previous 4 weeks (cough, wheezing, shortness of breath, etc.) which, in the opinion of the investigator, would elevate the participant's risk of adverse effects to WRAP exposure.
- Use of sedating cold/allergy medications in the previous week.
- Use of marijuana in the previous week.
- Consumption of alcohol in the previous 24 hours.
- Kidney or liver disease.
- Thyroid disease.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rutgers-EOHSI
Piscataway, New Jersey, 08854, United States
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Jose G Cedeno-Laurent, ScD
Rutgers, The State University of New Jersey: New Brunswick/Piscataway Campus
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- outside laboratories processing blood samples
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
August 25, 2025
First Posted
September 3, 2025
Study Start
September 18, 2025
Primary Completion
November 20, 2025
Study Completion
November 20, 2025
Last Updated
December 2, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share
There is no plan to make individual participant data available to other researchers.